OBJECTIVE: Weight gain is a frequently documented side effect after long-term anti-in¯ammatory treatment with systemic corticosteroid drugs in patients with asthma. In recent years new types of inhaled corticosteroids have been introduced, which act locally and are more rapidly bio-transformed. Even such corticosteroids may have a detectable, clinically relevant systemic side effect on weight. The aim of this study is to investigate if there is any relationship between body weight and asthma medication. DESIGN: The relationship between asthma medication and body weight was analysed in two combined randomized samples of the adult Swedish population 16 ± 60 y of age (n 17,912). Multivariate logistic regression analyses were carried out to obtain estimates for (1) body mass index (BMI) indicating`obesity' (BMI b29.9 kgam 2 ) in men and women controlling for self-reported asthma medication, and (2) self-reported asthma medication controlling for BMI. In both cases we furthermore controlled for interview period, age, Swedish region, smoking habits, physical activities and level of education. RESULTS: We found no signi®cantly higher odds for obesity in men (OR 1.21 (0.55 ± 2.64) or women (OR 1.97 (0.89 ± 4.38) on asthma medication compared to men and women with pharmacologically untreated asthma even after adjustment for smoking habits, physical activities, level of education and other related co-variables. However, we found signi®cant positive associations between obesity and interview period, age and former smoking and inverse signi®cant relationships with the degree of physical activity. We also found signi®cantly higher adjusted odds for asthma, indicated by self-reported asthma medication, in women (OR 2.74 (1.91 ± 3.91)) but not in men (OR 1.57 (0.96 ± 2.56)) with BMI indicating`obesity'. CONCLUSION: There is no strong evidence to suggest that modern pharmacological asthma treatment may contribute much to the development of obesity in either men or women on asthma medication. Adjustment for smoking habits, physical activities, level of education and other related co-variables have minor effects on these relationships. Obesity may still be an independent risk factor for asthma since we observed signi®cantly higher odds for self-reported asthma medication in women and an almost signi®cant relationship in men even after control for BMI and other related co-variables.
Introduction
During the 1950s and 1960s weight gain was one of the most frequently documented adverse side effects of corticosteroid treatment for patients with asthma. 1 In recent years new types of inhaled corticosteroids have been introduced, which act locally and are more rapidly bio-transformed. However, there is still a possibility that such corticosteroid drugs have detectable, clinically relevant systemic side effects.
Corticosteroids, b 2 agonists, and theophylline have been the most common drugs for treatment of asthma during the past three decades, 2 and self-reported information about the use of medication against asthma will embrace essentially these three antiasthmatic drugs. Since studies have shown weightreducing effects of b 2 agonists 3,4 and theophylline, 5 it is reasonable to assume that a positive association between self-reported medication against asthma and body weight to a certain extent could be attributed to the use of corticosteroids if other important risk or confounding factors could be controlled for.
Corticosteroids are the most potent and effective anti-in¯ammatory drugs and thus have a central role in the treatment of asthma, both in the form of systemic steroids in acute asthma and inhaled steroids in maintenance treatment. 6, 7 In 1995 about 54% of Swedish patients with bronchial asthma were treated with inhaled glucocorticoid drugs (ATC-group R03B A) and 12% with systemic corticosteroid drugs (ATCgroup H02) according to a Diagnose-Prescription study from The National Cooperation of Swedish Pharmacies. 8 The prescription of glucocorticoid drugs in Sweden has increased dramatically from 10.3 to 76.4 prescriptions per 1000 inhabitants and year between 1980 to 1994. During the same period there was a more than 29-fold increase in the sales of glucocorticoid drugs from 0.7 to 19.2 de®ned daily doses (DDD) per 1000 inhabitants and day.
b 2 agonist drugs are the most commonly used drugs for asthma. They act primarily on smooth muscle and are an effective form of bronchodilator treatment. They relieve symptoms generated by histamine and other bronchoconstrictors after exposure to allergens but do not affect the underlying in¯ammation. 2, 9 It is recognized that the b 2 -receptor is the dominant badrenoceptor mediating lipolysis in human fat cells. 3 A marked association between circulating lipids, lipoproteins and the ability of adipocytes to break down triglycerides, measured as the lipolytic b-adrenoceptor sensitivity of fat cells, has also been found. 3 Amoroso et al 4 have furthermore shown that inhalation of a b agonist (salbutamol) signi®cantly increases resting metabolic rate in a dose-dependent manner. Patients with chronic air¯ow limitations may also have raised energy requirements because of a need to expand the thoracic cage and loss of ef®ciency of the diaphragm. 10 Although relief of bronchoconstriction can reduce ventilation and offset any drug induced increase in ventilation, 11 it seems likely that adrenergic b 2 stimulating drugs per se would rather result in weight reduction than in weight gain.
Theophylline is not commonly used for routine treatment of asthma, but is used more extensively for patients with chronic obstructive airway disease (COPD) andaor emphysema. 2, 12 Theophylline inhibits late responses to allergen challenge with inhibition of allergen-induced migration of eosinophils into the lung. 13 However, the bronchodilator activity of oral theophylline is less effective than the b 2 agonists and high doses are needed, which increases the risk for toxic effects. 2, 12 Of interest for this discussion is that weight-reducing treatment of obesity has been suggested as a novel indication for theophylline. 5 Thus, it is unlikely that theophylline will promote the development of obesity among persons who take medicine against asthma.
Another cause for concern is if obesity may be an independent risk factor for asthma and not just a consequence of the disease or the disease treatment. 14 Since we cannot study the direction of the relationship in a cross-sectional study we will examine both aspects of the relationship. If the interviewed subject ®rst answers whether heashe has asthma and in the case of a con®rmed answer also reports that heashe has taken medicine against asthma for at least 14 days during the last year, the medical`validity' of the selfreported asthma complaints is probably more certain. It is then reasonable to assume that self-reported asthma medication may serve both as a test of the hypothesis that asthma is a cause to or an effect of obesity, or both. The other missing cases were in hospitals, institutions or simply not available. Although the dropout rate was rather high, we do not believe this will introduce a systematic error with regard to the main variables of interest for this study. Subjects who receive medication against asthma are primarily treated in primary care and thus ought to be available for interviews to about the same extent as the general population.
Materials and method
Clinically it is often dif®cult to separate asthma (reversible airway obstruction due to bronchial hyperreactivity) from COPD (a disease with irreversible airway obstruction). All calculations of variables in the present study of the Living Condition Surveys 1988a1989 and 1996a1997 therefore were limited to subjects between 16 and 60 y of age to exclude most subjects with COPD. Furthermore, osteoporosis and fractures have been the most common major complications of long-term oral or parenteral corticosteroid therapy for asthma. 15 Corticosteroids adversely affect calcium metabolism, eventually with harmful effects on bone formation and bone resorption. 16 An age restriction can also exclude older asthma patients exposed to longterm corticosteroid use with spinal osteoporosis and vertebral collapse, which otherwise may affect height and obscure the interpretation of BMI.
Cut-off points
In accordance with the new guidelines suggested by WHO, 17 a BMI value equal or higher than 30.0 kgam 2 was used to obtain estimates for obesity from selfreported weight (`How much do you weigh?') and height (`How tall are you?') in the analyses of the Living Condition Surveys. Men and women with a relative body weight lower than 30.0 were used as non-obese control groups. In tables where asthma medication was the dependent variable, subjects with BMI values below 18.5 were classi®ed as underweight, 18.5 ± 24.9 as normal and 25.0 ± 29.9 as overweight. These cut-off points apply to both men and women and to all adult age groups. The BMI range for men varied from 14.8 to 53.7 and for women from 12.5 to 63.1. One extreme value (BMI 9.0) for a Body weight characteristics of subjects on asthma medication A Hedberg and S Ro Èssner 44-y-old woman was excluded because of a probable error in coding.
Accuracy of self-reported weight and height
A methodological problem with estimation of relative weight (BMI) from self-reported weight and height is the accuracy of these measures. Several studies have been conducted where self-reported weight and height have been compared with objective measures. In a study of the questionnaires of this database, reported and recorded measurements were compared. The authors found a`¯at slope syndrome' with underreporting of height and over-reporting of low values for weight and BMI for both sexes. The results suggested an underestimation rather then an overestimation compared to objective weights and BMI. 18 Although the accuracy of the reported weights and heights in the present set of data from the Living Condition Survey were not controlled by other methods, it seems likely that an underestimation rather then an overestimation would be the case also in the present study.
Other variables
In the Living Condition Surveys 1988a1989 and 1996a1997 the question about self-reported asthma (`Do you have asthma?') was followed by another question concerning medication against asthma (`Have you taken medication against your asthma for at least 14 days (2 weeks) during the last year?'; Yes' or`No'). Subjects were also asked about their smoking habits (`Do you smoke daily?';`Yes' or No'). Former smokers were identi®ed by an additional question (`Have you ever smoked daily during any part of your life?'). The interviewed subjects were also asked about their degree of physical activity (`I would like to know how much exercise you get in your leisure time?'). The questions concerning exercise had ®ve different levels. Data were combined in three strata with regard to degree of exercise (stratum 1:`Gets practically no exercise at all'; stratum 2: Exercise now and then'; stratum 3:`Regular exercise',`Regular exercise twice a week' or`Regular, rather heavy exercise'). We also controlled for interview period (1988a1989 vs 1996a1997) and age (16 ± 30, 31 ± 45 and 46 ± 60 y). The communities of residence were classi®ed into four Swedish regions from south to north, since studies have shown higher prevalence of asthma in the northern part of the country. 19, 20 The level of education was used as a proxy for socio-economic status. The answers were categorized in three levels (compulsory school level, upper secondary level and graduate level).
Statistical analyses
Basic descriptive statistics were computed with the Freq procedure in the SAS-package. 21 A case control design (2Â2 tables) was used to test the relationship between body mass index indicating`obesity' (BMI b29.9) and non-obese controls in each level of variables in the study. Crude odds ratios and test-based 95% con®dence intervals were calculated for the Mantel ± Haenszel point estimate. 22 Since the cut-off points for`obesity' were the same for men and women, prevalence, odds ratios and con®-dence intervals 22 were strati®ed by sex (Tables 1 and  2 ). Chi-square for trend was calculated with Epi Info, Version 6. 23 Prevalence odds ratios (OR) are used for estimations of the relative risk (RR). When the RR is larger than 1, the OR is always larger than the RR. In cases with high prevalence the relative risk will give a better estimate, which should be observed when the odds ratios are interpreted. 24, 25 Multivariate logistic regression analyses were carried out with Proc Logistic in the SAS-system. 26 Point estimates and 95% con®dence intervals for obesity were obtained from self-reported weight and height in adult men and women after adjustment for medicated and non-medicated asthma and other related covariables ( Table 3) . The same multivariate analysis tools 26 were used to obtain odds ratios for self-reported asthma medication in men and women after adjustment for BMI categories and other related covariables (Table 6) .
Results
Asthma medication and other risk factors for obesity (BMI b29.9) Univariate analyses of prevalence rates, crude odds ratios, 95% con®dence intervals and chi-square for trend for obesity in relation to investigated risk factors are presented in Tables 1 and 2 . We found a signi®-cantly higher risk for obesity in women on asthma medication (OR 2.58 (1.83 ± 3.63)) compared to women with no asthma (Table 2 ), but this association almost disappeared when women with non-medicated asthma were used as reference group (Table 2, note 2). There was no enhanced risk for obesity in men on asthma medication regardless of which reference group that was used ( Table 1 ). The strongest association was found between obesity and age in both sexes. We furthermore found signi®cant associations between obesity and interview period, smoking habits, degree of physical activities and level of education in both men and women (Tables 1 and 2 ).
In the multivariate logistic regression analyses (Table 3) we found no enhanced odds for obesity in either men or women compared to subjects with nonmedicated asthma. However, the estimated odds ratios for obesity were still signi®cantly related to interview period, older age (31 ± 45, 46 ± 60), former smoking, Body weight characteristics of subjects on asthma medication A Hedberg and S Ro Èssner Chi square if medicated asthma is the exposed and non-medicated asthma the non-exposed reference group (OR 2.16 (0.95 ± 5.12)) excluding women with no asthma. Chi square if medicated asthma is the exposed and non-medicated asthma the non-exposed reference group (OR 1.17 (0.52 ± 2.68)) excluding men with no asthma.
Body weight characteristics of subjects on asthma medication A Hedberg and S Ro Èssner no or only occasional physical activities and level of education.
Obesity' and other risk factors for asthmaaasthma medication
Univariate analyses were also carried out for men and women on self-reported asthma medication (Tables 4  and 5 ). We found a signi®cantly enhanced odds ratio for`asthma', indicated by asthma medication, in women (OR 2.83 (1.99 ± 4.02)) and an almost signi®cant association in men with`obesity' (OR 1.62 (0.99 ± 2.64)) compared to men vs women with acceptable weight. In the multiple logistic regression analyses (Table 6 ) the estimated odds ratios for asthma medication was reduced in strength, but still highly signi®cant, in women with`obesity' (OR 2.74 (1.91 ± 3.91)), but not quite signi®cant in men with obesity' (OR 1.57 (0.96 ± 2.56)), compared to women and men in the normal weight range. We found enhanced adjusted odds ratios for medicated asthma in both men and women between the interview periods 1988a1989 and 1996a1997. There was also signi®cantly lower consumption of asthma medication in middle-aged men and women compared to younger adults (16 ± 30 y of age). Finally, we found signi®cantly higher prevalence and adjusted odds ratios for men on asthma medication in the most northern part of the country (Table 6) .
Discussion
A few decades ago weight gain was a frequently documented side effect after long-term anti-in¯am-matory treatment with systemic corticosteroid drugs in patients with asthma. 1, 27, 28 In the present study we hypothesized that even inhaled corticosteroid drugs might have a detectable, clinically relevant side effect on body weight, although it was not possible to separate the effects of oral from inhaled corticosteroids. Many patients may also receive intermittent courses of oral corticosteroids, which could further confound the interpretation. However, if the combined effects of oral and inhaled corticosteroid drugs were suf®ciently high to affect body weight they ought to be able to be detected even by a question about selfreported medication against asthma (`Have you taken medicine against your asthma for at least 14 days (2 weeks) during the last year?')
The risk for weight gain after systemic administration of corticosteroid drugs is well known and related Body weight characteristics of subjects on asthma medication A Hedberg and S Ro Èssner Men with non-medicated asthma excluded. Mantel ± Haenszel test for linear association.
Body weight characteristics of subjects on asthma medication A Hedberg and S Ro Èssner to the dose and duration necessary during long-term anti-in¯ammatory treatment. 1, 28 Since inhaled corticosteroids have detectable systemic effects it is also possible that the remaining bioavailable steroid might have clinical effects if given in suf®ciently high doses during a longer period of time. 27, 31, 35 According to a Diagnose-Prescription study from The National Cooperation of Swedish Pharmacies carried out in 1995, the proportion of asthma patients treated with systemic corticosteroid drugs (ATC-group H02) was surprisingly high (12%).
The results from the logistic regression analyses did not indicate signi®cantly higher adjusted odds ratios for obesity in men or women on asthma medication compared to men and women with non-medicated asthma, although the odds ratio was almost doubled in women (OR 1.97 (0.89 ± 4.38)). Thus, there was no strong evidence to suggest that modern asthma medication had contributed signi®cantly to the development of obesity in subjects with self-reported asthma in the adult Swedish population, possibly because of a tendency to use`adrenal-sparing' inhaled corticosteroids more commonly in recent years. It is also possible that the non-signi®cant result in women could be explained by poor compliance with inhaled corticosteroids, which could dilute the strength of the association between obesity and asthma medication.
Another confounding issue is the possible effect of asthma and its medication on growth in children and ®nal height. Chronic asthma has been associated with prepubertal deceleration of growth velocity, which may resemble growth retardation. However, decelerated growth in these children is usually accompanied by retarded bone age on X-ray and later`catch-up' growth, while expected height is normally attained. 35 The signi®cantly higher adjusted odds ratios for asthma medication in women with both overweight (OR 1.42 (1.10 ± 1.84)) and obesity (OR 2.74 (1.91 ± 3.91)) could indicate a causal relationship where obesity is an independent risk factor for asthma (indicated by asthma medication) and not just a consequence of the disease. Preliminary results from the American Longitudinal Nurses Health Study have shown that fatness precedes the onset of asthma. 29 Several studies have also found a continuous dose ± response relationship showing a higher prevalence of asthma with higher BMI. 30 A sedentary lifestyle has been causally related to asthma. 14, 32 In the present study we found a signi®-cantly higher odds ratio for asthma medication in men Body weight characteristics of subjects on asthma medication A Hedberg and S Ro Èssner (OR 1.50 (1.02 ± 2.21)) and an enhanced, but not quite signi®cant odds ratio in women (OR 1.29 (0.93 ± 1.80)) who got practically no exercise at all. Platts-Mills and colleagues 32 have suggested that a reduction in deep breathing, associated with a sedentary lifestyle, may reduce the extent to which the bronchial muscle is stretched, which in turn may lead to airway narrowing. It is also possible that the fear of exercise-induced bronchoconstriction could lead to less physical activity and weight gain. Cigarette smoking may contribute to the initiation of an in¯ammatory response that is deleterious to the normal function of the lung. 33 However, in the present study we found no signi®cant association between medicated asthma and former or daily smokers in either of the sexes. Many risk factors such as smoking, physical inactivity and poor diet are clustered in lower socio-economic strata. 34 Thus, socio-economic status is an important confounder of a possible relationship between obesity and asthma. In the present study we used the level of education as a proxy for socioeconomic status. We found signi®cantly lower adjusted odds for obesity with higher level of education in both men and women. However, the estimated adjusted odds ratios for asthma, here indicated by selfreported asthma medication, were not signi®cantly enhanced at any level of education.
The major limitation of this study is that we could not differentiate between various kinds of asthma medications or between oral and inhaled administrations of the drugs. There are signi®cant differences between systemic effects of different corticosteroids; the effects on adrenal suppression are both doserelated and medication-speci®c (ie beclomethasone vs budesonide). However, assuming corticosteroids are the only anti-asthmatic drugs with systemic effects that could result in weight gain, self-reports on the use of asthma medications compared to non-medicated asthma may still serve the purpose of testing body weight change in subjects on asthma medication.
In summary, signi®cant positive relationships were found between obesity and interview period, age and previous smoking; inverse relationships with physical activity and level of education. Although an effect on body weight from asthma medication can be suspected on analysis of the sample comparing nonasthmatic subjects to those on asthma medication, at least in women, these differences mostly disappear when the comparison is performed between medicated and non-medicated asthmatic subjects. b 2 agonists and theophylline for asthma treatment principally result in weight loss, leaving corticosteroids as prime suspects for any treatment-associated weight gain. However, the estimated adjusted odds ratios for obesity were not signi®cantly enhanced in men or women on asthma medication compared to those with pharmacologically untreated asthma. Obesity may still be an independent risk factor for asthma since signi®cantly higher odds for medicated asthma were found in women and an almost signi®cant association in men even after control for BMI categories and other related co-variables. Support for a causal relationship has to be further documented in cohort studies. Studies of the relationship between obesity and asthma is of obvious clinical concern since a recent study has shown that weight reduction in obese patients with asthma improves lung functions, symptoms, morbidity and health status. 36 
